Clinical Trials

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01496976 2025-12-19

Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL

45 enrolled 12 charts

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02877303 2025-11-06

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

Phase 2 Recruiting

80 enrolled

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT01258933 2025-10-01

Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy

Phase 2 Terminated

4 enrolled 7 charts

Phase 2 Active not recruiting

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06867991 2025-07-15

RADIA

Phase 3 Recruiting

200 enrolled

Autoimmune Diseases of the Nervous System, Anti-N-Methyl-D-Aspartate Receptor Encephalitis

NCT01361711 2025-05-23

Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

53 enrolled 10 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01352312 2025-04-29

Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma

Phase 1 Terminated

10 enrolled

Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT01437709 2025-02-28

Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant

30 enrolled 15 charts

Lymphoma, Mantle-Cell

NCT02388048 2025-01-29

Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia

19 enrolled

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01243190 2024-09-19

Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

44 enrolled 7 charts

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03488225 2024-07-16

Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia

Phase 2 Terminated

4 enrolled 11 charts

Burkitt Lymphoma

NCT02199184 2024-06-11

Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia

14 enrolled 10 charts

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01527149 2024-02-07

Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

37 enrolled 19 charts

Lymphoma, Mantle-Cell

NCT01145209 2023-11-28

Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL

32 enrolled 16 charts

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04189588 2023-10-06

versus

34 enrolled 11 charts

Oncology Patients Receiving Chemotherapy

NCT01060384 2023-10-04

Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 1/2 Completed

46 enrolled 8 charts

Lymphoma, Non-Hodgkin

NCT02004522 2023-09-21

A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)

319 enrolled 18 charts 1 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02049515 2023-09-21

A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07

99 enrolled 11 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03280160 2022-09-16

Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab

Phase 2 Unknown

84 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02710643 2022-06-21

FIL_MIRO

110 enrolled

Lymphoma, Lymphoma, Follicular

NCT01481272 2021-12-27

PLRG8

77 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT01190449 2021-08-18

Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

51 enrolled 7 charts

Lymphoma, Lymphoma, Follicular

NCT01444716 2021-07-26

Ofatumumab as Front-Line Therapy in Treating Elderly Participants With Chronic Lymphocytic Leukemia

34 enrolled 9 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01613300 2021-05-26

Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients

33 enrolled

Disease, Lymphoma, B-Cell

NCT01363128 2021-05-03

Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

72 enrolled 10 charts

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01497496 2021-04-27

Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

29 enrolled 9 charts

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01088048 2021-03-18

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Phase 1 Completed

241 enrolled 31 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT01329900 2020-07-08

Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas

50 enrolled 7 charts

Lymphoma

NCT02689141 2020-06-11

Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)

66 enrolled

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01578707 2019-12-18

RESONATE™

391 enrolled 14 charts

Bronchiolitis Obliterans Syndrome, Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01532700 2019-09-24

An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)

28 enrolled 12 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01659021 2019-08-14

Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia

Phase 3 Terminated

261 enrolled 21 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01039376 2019-07-30

PROLONG

Phase 3 Terminated

480 enrolled 30 charts

Leukemia, B-Cell

NCT00748189 2019-06-25

COMPLEMENT 1

Phase 3 Terminated

447 enrolled 32 charts

Neoplasms, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01002755 2019-05-07

Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Classical hematologyLymphoidOther hematologic neoplasm

36 enrolled 7 charts

Lymphadenopathy, Agammaglobulinemia, Fatigue, Fever, Lymphocytosis, Paraproteinemias, Thrombocytopenia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01024010 2018-09-18

Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

82 enrolled 10 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01294579 2018-08-09

Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)

49 enrolled 13 charts

Lymphoma, Non-Hodgkin, Recurrence

NCT02419469 2018-06-11

Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Phase 2 Terminated

1 enrolled 4 charts

Leukemia, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01191190 2018-05-08

CRC027

21 enrolled 12 charts

Leukemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01171378 2018-04-25

CHOP-OR

43 enrolled

Lymphoma, Non-Hodgkin

NCT01626352 2017-11-22

Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy

22 enrolled 14 charts

Lymphoma, Large B-Cell, Diffuse

NCT00742144 2017-11-17

Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia

Phase 1 Completed

6 enrolled

Bronchiolitis Obliterans Syndrome, Leukemia, Lymphoma, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01110031 2017-11-13

Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia Subjects

Phase 1 Completed

12 enrolled

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01848145 2017-06-06

Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia

34 enrolled 10 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00811733 2017-05-30

A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia

37 enrolled 25 charts

Waldenstrom Macroglobulinemia

NCT01077622 2017-05-30

A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia

10 enrolled 35 charts

Leukemia, B-Cell

NCT01580228 2017-02-23

A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)

44 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01520922 2017-01-19

Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

99 enrolled 27 charts

Leukemia, Lymphoid, Neoplasms, Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01113632 2016-09-20

Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

77 enrolled 9 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01809847 2016-09-19

Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation

20 enrolled